Breaking Finance News

Sage Therapeutics (NDAQ:SAGE) target price raised to $117.00, issued a report today by RBC Capital Markets

Yesterday Sage Therapeutics (NDAQ:SAGE) traded -2.10% lower at $62.31. The company’s 50-day moving average is $81.85 and its 200-day moving average is $74.87. The last closing price is down -15.20% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 473,504 shares of the stock were exchanged, down from an average trading volume of 527,362

Sage Therapeutics (NDAQ:SAGE) had its target price raised to $117.00 by RBC Capital Markets in a report released 9/15/2017. The new target price indicates a possible upside of 0.88% based on the company's last closing price.

Previously on 9/13/2017, Needham reported on Sage Therapeutics (NDAQ:SAGE) lowered the target price from $95.00 to $86.00. At the time, this indicated a possible upside of 0.19%.

See Chart Below

Sage Therapeutics (NDAQ:SAGE)

Sage Therapeutics has a 52 week low of $38.30 and a 52 week high of $90.80 The company’s market cap is currently $0.

In addition to RBC Capital Markets reporting its target price, a total of 8 brokers have issued a report on the stock. The consensus target price is $68.88 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Sage Therapeutics (NDAQ:SAGE)

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.